HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 202 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q3 2023. The put-call ratio across all filers is 0.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $178,603,338 | -7.2% | 5,450,209 | -0.4% | 0.02% | -6.2% |
| Q2 2023 | $192,497,996 | -47.3% | 5,470,247 | -51.1% | 0.02% | -5.9% |
| Q1 2023 | $365,129,850 | +18.7% | 11,183,150 | +100.3% | 0.02% | -45.2% |
| Q4 2022 | $307,608,321 | +23.7% | 5,582,728 | -0.6% | 0.03% | +19.2% |
| Q3 2022 | $248,704,000 | -6.0% | 5,615,339 | +3.5% | 0.03% | 0.0% |
| Q2 2022 | $264,664,000 | +11.1% | 5,426,782 | +10.8% | 0.03% | +36.8% |
| Q1 2022 | $238,249,000 | +32.8% | 4,897,182 | +16.4% | 0.02% | +46.2% |
| Q4 2021 | $179,412,000 | +13.4% | 4,207,599 | +1.9% | 0.01% | 0.0% |
| Q3 2021 | $158,263,000 | +13.5% | 4,128,951 | -16.4% | 0.01% | +18.2% |
| Q2 2021 | $139,499,000 | -41.8% | 4,941,527 | -31.8% | 0.01% | -45.0% |
| Q1 2021 | $239,555,000 | -12.6% | 7,250,441 | -8.5% | 0.02% | -16.7% |
| Q4 2020 | $273,956,000 | -2.1% | 7,926,624 | -12.5% | 0.02% | -14.3% |
| Q3 2020 | $279,975,000 | – | 9,064,036 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |